Howe & Rusling’s Taiwan Liposome TLC Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2020
Q4
– Sell
-500
Closed -$2K – 1025
2020
Q3
$2K Hold
500
– – ﹤0.01% 749
2020
Q2
$3K Hold
500
– – ﹤0.01% 650
2020
Q1
$2K Hold
500
– – ﹤0.01% 670
2019
Q4
$3K Hold
500
– – ﹤0.01% 648
2019
Q3
$3K Hold
500
– – ﹤0.01% 656
2019
Q2
$3K Hold
500
– – ﹤0.01% 639
2019
Q1
$3K Buy
+500
New +$3.08K ﹤0.01% 644

Other funds holding TLC

Howe & Rusling's TLC Position: Q4 2020 in Review

Howe & Rusling sold out of Taiwan Liposome (TLC) in Q4 2020, closing a stake of 500 shares — an estimated $2K sold.

Howe & Rusling first reported a position in TLC in Q1 2019 and held it in 7 quarters. The position peaked at $3K in Q2 2020. 4 funds tracked by Wall St. Rank hold TLC as of Q4 2020.

  • Howe & Rusling reported no remaining Taiwan Liposome position as of Q4 2020 after selling out during the quarter.
  • Howe & Rusling sold 500 Taiwan Liposome shares in Q4 2020, an estimated $2K.
  • Howe & Rusling first reported a position in Taiwan Liposome in Q1 2019 and held it in 7 quarters.
  • Howe & Rusling's Taiwan Liposome position peaked at $3K in Q2 2020.
  • 4 funds tracked by Wall St. Rank held Taiwan Liposome as of Q4 2020.

Based on Howe & Rusling's 13F filing for Q4 2020, filed 8 Feb 2021.